Viracta Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application 18/240,853 Titled "HDAC INHIBITOR SOLID STATE FORMS (FOR THE TREATMENT OF CANCER, IMMUNE DISORDERS, AND INFLAMMATION)"
Viracta Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application 18/240,853 Titled "HDAC INHIBITOR SOLID STATE FORMS (FOR THE TREATMENT OF CANCER, IMMUNE DISORDERS, AND INFLAMMATION)"
Viracta治療已收到美國專利申請18/240,853的通知書，標題爲「HDAC抑制劑固態形式（用於治療癌症，免疫紊亂和炎症）」
Viracta Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application 18/240,853 Titled "HDAC INHIBITOR SOLID STATE FORMS (FOR THE TREATMENT OF CANCER, IMMUNE DISORDERS, AND INFLAMMATION)"
Viracta治療已收到美國專利申請18/240,853的通知書，標題爲「HDAC抑制劑固態形式（用於治療癌症，免疫紊亂和炎症）」
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。